VISUfarma, a wholly owned subsidiary of Lupin, has entered into an exclusive licensing agreement with Visus Therapeutics, a wholly owned subsidiary of Tenpoint Therapeutics, according to an announcment from Lupin.

The partnership provides VISUfarma the exclusive rights to undertake regulatory activities, commercialization, marketing, promotion, distribution, and sale of Yuvezzi (carbachol and brimonidine tartrate ophthalmic solution) 2.75%/0.1% in the European Union, the United Kingdom, Switzerland, Norway, and Iceland (licensed territories). Yuvezzi is a proprietary ophthalmic product indicated for the treatment of presbyopia in adults. Under the agreement, VISUfarma will make a strategic investment in Visus. Tenpoint and Visus, individually or collectively, will also be eligible to receive regulatory and commercial milestone payments and tiered royalties based on net sales.

“We are delighted to partner with Tenpoint Therapeutics to bring a novel ophthalmic therapy that advances our specialty care strategy,” said Vinita Gupta, CEO of Lupin. "Building on the strategic acquisition of VISUfarma, this partnership further strengthens our vision care franchise and expands our presence across key European markets. The addition of Yuvezzi underscores our commitment to broadening access to differentiated therapies, improving patient outcomes, and reinforcing our leadership in eye care across the licensed territories.”

"This exciting partnership marks an important step for Tenpoint as we continue our work to make Yuvezzi available for the millions of patients with presbyopia and eye care professionals around the world,” said Henric Bjarke, CEO of Tenpoint. "Lupin’s strong commercial operations span major European markets, and its specialty ophthalmology company VISUfarma’s longstanding presence in eye care makes them an excellent partner. We look forward to working together as we bring Yuvezzi to Europe.” 

As the first and only approved once-daily, dual-agent eye drop for presbyopia, Yuvezzi's addition to Lupin’s ophthalmology portfolio supports the company’s strategy for expanding its specialty care business through innovative therapies that address significant unmet patient needs.

Tenpoint is advancing commercialization of Yuvezzi in the United States following the product's recent FDA approval, further expanding the reach of Yuvezzi through strategic regional partnerships worldwide. In addition, Tenpoint has submitted a Marketing Authorization Application to the United Kingdom’s Medicines and Healthcare products Regulatory Agency via the agency's International Recognition Procedure. The company will continue to execute its plans for regulatory applications for Yuvezzi in other key regions worldwide.